

RECEIVED

PTO/SB/08A		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/843,132
		Filing Date	April 25, 2001
		Confirmation Number	8349
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	1614
		Examiner Name	Unknown
Sheet 1 of 3	Attorney Docket No.	PHA 4301 (3167/12Z)	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
N	1.	4,100,274		Dutta et al.	07-11-1978
N	2.	4,140,707		Cleare et al.	02-20-1979
N	3.	5,696,131		Baguley et al.	12-09-1997
N	4.	5,733,909		Black et al.	03-31-1998
N	5.	5,767,142		LaVoie et al.	06-16-1998
N	6.	5,824,699		Kreft et al.	10-20-1998
N	7.	5,869,524		Failli	02-09-1999


FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
N	8.	EP	0 835 938	A2	Smithkline Beecham Corporation	04-15-1998	
N	9.	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
N	10.	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
N	11.	WO	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994	

Examiner Signature	<i>[Signature]</i>	Date Considered	12/15/03
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A				<b>Compl te if Known</b> Application Number 09/843,132 Filing Date April 25, 2001 Confirmation Number 8349 First Named Inventor John P. McKearn et al. Group Art Unit 1614 Examiner Name Unknown	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 				Sheet 2 of 3 Attorney Docket No. PHA 4301 (3167/12Z)	

h	12.	WO	94/25431	A1	The Welcome Foundation Limited	11-10-1994	
h	13.	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994	
h	14.	WO	94/27980	A1	G.D. Searle & Co.	12-08-1994	
h	15.	WO	95/11883	A1	G.D. Searle & Co.	05-04-1995	
h	16.	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
h	17.	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995	
h	18.	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995	
	19.	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996	
h	20.	WO	96/03392	A1	G.D. Searle & Co.	02-08-1996	
h	21.	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996	
h	22.	WO	96/21667	A1	Merck Frosst Canada Inc.	07-18-1996	
h	23.	WO	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996	
h	24.	WO	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996	
h	25.	WO	96/36623	A1	Merck Frosst Canada Inc.	11-21-1996	
h	26.	WO	96/37469	A1	Merck Frosst Canada Inc.	11-28-1996	
h	27.	WO	97/15676	A2	Abbott Laboratories	05-01-1997	
h	28.	WO	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997	
h	29.	WO	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997	

Examiner Signature		Date Considered	12/15/03
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/843,132		
		Filing Date	April 25, 2001		
		Confirmation Number	8349		
		First Named Inventor	John P. McKearn et al.		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet	3	of	3	Attorney Docket No.	PHA 4301 (3167/12Z)

RECEIVED  
AUG 19 2003  
TECH CENTER 1600/3900

1	30.	WO	97/36863	A1	Merck Frosst Canada Inc.	10-09-1997	
1	31.	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	
1	32.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998	
1	33.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998	
1	34.	WO	98/25896	A1	G.D. Searle & Co.	06-18-1998	
1	35.	WO	98/40104	A2	Yale University et al.	09-17-1998	
1	36.	WO	99/05104	A1	Pfizer Pharmaceuticals Inc.	02-04-1999	
1	37.	WO	99/10331	A1	Abbott Laboratories	03-04-1999	
1	38.	WO	99/12930	A1	Glaxo Group Limited	03-18-1999	
1	39.	WO	99/14194	A1	Merck Frosst Canada Inc.	03-25-1999	
1	40.	WO	99/14205	A1	Almirall Prodesfarma S.A.	03-25-1999	
1	41.	WO	99/41241	A1	Rutgers, The State University of New Jersey	08-19-1999	

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	42.	<del>International Search Report for Application No. PCT/US02/13219, dated January 13, 2003</del>	
1	43.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages <sup>1</sup> , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58	

Examiner Signature	<i>McKearn</i>	Date Considered	12/15/03
--------------------	----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.